Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00443534 · ClinicalTrials.gov registry record · NA

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

A NA study of Neoplasms, sponsored by Pfizer.

Completed
Registry status
NA
Development phase
123
Enrollment target
20
Study locations

NCT00443534 is a NA study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 123 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00443534, a NA study of Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
NA
Development phase
123 participants
Enrollment target
20
Study locations

Study Summary

This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.

Conditions Studied

Neoplasms

Interventions

  • DRUG SU011248

Study Locations (20)

Illinois

  • Pfizer Investigational Site - Harvey
  • Pfizer Investigational Site - Harvey
  • Pfizer Investigational Site - Maywood
  • Pfizer Investigational Site - Tinley Park
  • Pfizer Investigational Site - Zion

Missouri

  • Pfizer Investigational Site - City of Saint Peters
  • Pfizer Investigational Site - Creve Coeur
  • Pfizer Investigational Site - St Louis

North Carolina

  • Pfizer Investigational Site - Chapel Hill
  • Pfizer Investigational Site - Clinton
  • Pfizer Investigational Site - Goldsboro

Colorado

  • Pfizer Investigational Site - Aurora
  • Pfizer Investigational Site - Littleton

Florida

  • Pfizer Investigational Site - Orlando

Georgia

  • Pfizer Investigational Site - Atlanta

Indiana

  • Pfizer Investigational Site - Munster

Maryland

  • Pfizer Investigational Site - Baltimore

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2006-05
Est. Completion 2011-12
Phase NA

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00443534

The ClinicalTrials.gov registry entry for NCT00443534 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (92% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which SU011248 is the first listed.

NCT00443534 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Illinois, Missouri, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00443534 about?

NCT00443534 is a clinical study titled "A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.". This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.

What is the current status of trial NCT00443534?

This trial is currently completed. It is a NA study. The enrollment target is 123 participants. The study started on 2006-05. Estimated completion is 2011-12.

What conditions does trial NCT00443534 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT00443534?

The interventions under investigation include: SU011248 (DRUG).

Who is sponsoring clinical trial NCT00443534?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00443534 being conducted?

This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.